BIAF logo

BIAF
BioAffinity Technologies Inc

3,887
Mkt Cap
$7.35M
Volume
90,633.00
52W High
$15.00
52W Low
$0.693
PE Ratio
-0.14
BIAF Fundamentals
Price
$1.62
Prev Close
$1.62
Open
$1.61
50D MA
$2.74
Beta
1.58
Avg. Volume
1.09M
EPS (Annual)
-$8.66
P/B
1.99
Rev/Employee
$108,104.54
$3.26
Loading...
Loading...
News
all
press releases
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung
bioAffinity posts softer first-quarter 2026 results after exiting lower-margin pathology services, though CyPath Lung adoption and clinical-trial progress gain traction.
News Placeholder
More News
News Placeholder
bioAffinity Technologies Reports Record Monthly CyPath Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...
News Placeholder
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath Lung
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases...
News Placeholder
bioAffinity Technologies Launches New Study To Expand Use of CyPath Lung Technology for Asthma and COPD Diagnosis and Treatment
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced a pilot study with Brooke Army...
News Placeholder
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
News Placeholder
New Case Study: bioAffinity Technologies CyPath Lung Diagnostic Supports Physicians Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new clinical case study...
News Placeholder
bioAffinity Technologies CyPath Lung to Be Featured at Cleveland Clinic Annual Advances in Early Lung Cancer Detection Symposium April 16
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, announces that its CyPath Lung test will be featured at...
News Placeholder
BIAF Stock Gains As CyPath Sales Surge 146% In Q1
The test is capable of identifying lung cancer at Stage 1A, enhancing chances for effective treatment.
News Placeholder
bioAffinity Technologies CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath Lung...
News Placeholder
UGRO, TURB, ANNA, EEIQ, BIAF: These Five Stocks Outpaced Big Tech With Massive March Returns
As big tech faltered during sector shifts, share prices of some of the smaller companies surged amid restructuring efforts and key business achievements.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available